The program is designed to enable Pulsenmore to develop and clinically validate AI applications that improve clinical workflow efficiency and enhance the scalability of the company's home ultrasound platform.

RAMAT GAN, Israel, July 13, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ:PLSM) (TASE: PLSM), a pioneer in connected home ultrasound technology, today announced that it has been selected to participate in Israel's Healthcare AI Regulatory Sandbox Program, established by the Israel Innovation Authority (IIA) and the Ministry of Health. Pulsenmore will receive funding from the IIA as part of a project.

The program is designed to accelerate the adoption of breakthrough healthcare AI technologies through a unique regulatory framework that enables companies to develop, evaluate and clinically validate innovative solutions in close collaboration with regulators and the healthcare system. Its objective is to establish a clear and efficient pathway for the integration of these technologies into healthcare systems in Israel and worldwide.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.